A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ADMA SEC filings page.
ADMA Biologics, Inc. (ADMA) reported $519.2M in revenue over the twelve months to Sep 30, 2026, up 6.3% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
ADMA scaled revenue rapidly and widened operating margins, but FY2025 cash generation weakened as receivables and reinvestment absorbed earnings.
The key shift is earnings-to-cash conversion: net income fell25.7% while operating cash flow fell57.5% , a much sharper deterioration than the reported profit change. Receivables increased216.9% and capital expenditures increased174.4% , tying the weaker cash result to working-capital absorption and heavier reinvestment rather than disappearing operating profit.
Revenue increased
Liabilities fell to
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of ADMA Biologics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. ADMA Biologics, Inc. scores 66/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. ADMA Biologics, Inc. scores 92/100 on it among other operating companies.
ADMA Biologics, Inc. held more cash than long-term debt at the end of fiscal year 2025, with $87.6M of cash against $69.3M of long-term debt. Operating companies are ranked here on long-term debt less cash against their EBITDA, where a lower multiple is the safer one, and ADMA Biologics, Inc. scores 79/100 among other operating companies measured the same way.
ADMA Biologics, Inc. held $6.71 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 6.71. Liquidity ranks operating companies on that ratio, and ADMA Biologics, Inc. scores 95/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. ADMA Biologics, Inc. scores 68/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. ADMA Biologics, Inc. scores 69/100 on it among other operating companies.
ADMA Biologics, Inc. scores 14.52, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $3.0B against total liabilities of $146.9M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
ADMA Biologics, Inc. passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
For every $1 of reported earnings, ADMA Biologics, Inc. generates $0.34 in operating cash flow ($50.4M OCF vs $146.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
ADMA Biologics, Inc. earns $26.93 in operating income for every $1 of interest expense ($191.4M vs $7.1M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
ADMA Biologics, Inc. generated $141.1M in revenue in Q3 2026. This represents an increase of 5.1% from the same quarter a year earlier. Against the prior quarter it is up 13.4%.
ADMA Biologics, Inc.'s EBITDA was $69.5M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 31.0% from the same quarter a year earlier. Against the prior quarter it is up 28.3%.
ADMA Biologics, Inc. reported $49.9M in net income in Q3 2026. This represents an increase of 36.9% from the same quarter a year earlier. Against the prior quarter it is up 31.9%.
ADMA Biologics, Inc. earned $0.22 per diluted share (EPS) in Q3 2026. This represents an increase of 46.7% from the same quarter a year earlier. Against the prior quarter it is up 37.5%.
Cash & Balance Sheet
ADMA Biologics, Inc. generated $15.4M in free cash flow in Q3 2026, representing cash available after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 43.7%.
ADMA Biologics, Inc. held $124.6M in cash against $191.6M in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
ADMA Biologics, Inc.'s gross margin was 70.8% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 14.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.4 percentage points.
ADMA Biologics, Inc.'s operating margin was 48.0% in Q3 2026, reflecting core business profitability. This is up 10.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.9 percentage points.
ADMA Biologics, Inc.'s net profit margin was 35.4% in Q3 2026, showing the share of revenue converted to profit. This is up 8.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.9 percentage points.
ADMA Biologics, Inc.'s quarterly ROE was 11.4% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 2.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.1 percentage points.
Capital Allocation
ADMA Biologics, Inc. invested $4.5M in research and development in Q3 2026. This represents an increase of 193.8% from the same quarter a year earlier. Against the prior quarter it is down 25.3%.
ADMA Biologics, Inc. spent $25.1M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 8.8% from the same quarter a year earlier. It is unchanged from the prior quarter.
ADMA Biologics, Inc. invested $2.0M in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 86.1% from the same quarter a year earlier. Against the prior quarter it is down 11.3%.
ADMA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $141.1M+5.1% | $124.4M+2.0% | $114.5M-0.3% | $139.2M+18.4% | $134.2M+12.0% | $122.0M+13.8% | $114.8M+40.2% | $117.5M+59.1% |
| Cost of Revenue | $41.2M-29.7% | $38.1M-30.4% | $33.7M-37.2% | $50.3M-7.1% | $58.6M-2.6% | $54.8M+10.1% | $53.7M+25.6% | $54.2M+26.6% |
| Gross Profit | $99.9M+32.1% | $86.3M+28.3% | $80.8M+32.2% | $88.8M+40.2% | $75.6M+26.8% | $67.2M+17.0% | $61.1M+56.2% | $63.3M+103.7% |
| R&D Expenses | $4.5M+193.8% | $6.0M+483.3% | $2.6M+214.4% | $1.4M+252.2% | $1.5M+270.9% | $1.0M+84.1% | $826K+83.6% | $391K-12.3% |
| SG&A Expenses | $26.6M+21.9% | $26.7M+20.4% | $26.7M+11.1% | $23.5M+0.8% | $21.8M+17.3% | $22.2M+33.8% | $24.1M+54.0% | $23.3M+50.1% |
| Operating Income | $67.8M+32.8% | $52.4M+22.5% | $58.3M+67.1% | $62.8M+63.7% | $51.0M+28.7% | $42.8M+9.2% | $34.9M+59.9% | $38.3M+169.3% |
| EBITDA | $69.5M+31.0% | $54.1M+20.9% | $60.1M+63.3% | $64.8M+60.6% | $53.0M+27.6% | $44.8M+9.0% | $36.8M+55.1% | $40.3M+149.9% |
| Interest Expense | $3.4M+104.9% | $3.4M+86.7% | $2.1M+6.3% | $1.6M-43.5% | $1.7M-52.1% | $1.8M-51.5% | $2.0M-47.6% | $2.9M-53.7% |
| Income Tax | $15.7M+41.8% | $12.4M+111.2% | $11.8M+80.2% | $12.2Mn/m | $11.1M+1219.9% | $5.9M+55.1% | $6.5M+1000.2% | -$77.2Mn/m |
| Net Income | $49.9M+36.9% | $37.8M+10.5% | $45.3M+68.5% | $49.4M-55.9% | $36.4M+1.4% | $34.2M+6.7% | $26.9M+51.1% | $111.9Mn/m |
| EPS (Basic) | $0.22+46.7% | $0.17+21.4% | $0.19+72.7% | $0.21-56.3% | $0.150.0% | $0.140.0% | $0.11+37.5% | $0.48n/m |
| EPS (Diluted) | $0.22+46.7% | $0.16+14.3% | $0.19+72.7% | $0.20-56.5% | $0.150.0% | $0.14+7.7% | $0.11+37.5% | $0.46n/m |
| Diluted Shares (Avg) | 226M-7.7% | 230M-7.3% | 240M-1.9% | N/A | 245M-0.1% | 249M+2.7% | 245M+3.5% | N/A |
ADMA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $732.5M+28.8% | $684.2M+22.5% | $665.2M+30.3% | $624.2M+27.7% | $568.7M+45.6% | $558.4M+48.3% | $510.6M+45.5% | $488.7M+48.5% |
| Current Assets | $575.9M+43.0% | $528.2M+32.2% | $511.2M+45.3% | $466.5M+40.8% | $402.7M+26.5% | $399.6M+31.6% | $351.8M+27.3% | $331.4M+28.9% |
| Cash & Equivalents | $124.6M+102.9% | $136.0M+50.7% | $138.2M+92.9% | $87.6M-15.0% | $61.4M-29.2% | $90.3M+2.3% | $71.6M+58.0% | $103.1M+100.9% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $266.1M+35.3% | $239.3M+25.0% | $222.1M+29.0% | $206.5M+21.3% | $196.7M+14.5% | $191.5M+6.5% | $172.2M-3.1% | $170.2M-1.5% |
| Accounts Receivable | $169.2M+22.9% | $138.2M+26.0% | $135.9M+36.7% | $158.4M+216.9% | $137.7M+174.6% | $109.7M+264.4% | $99.4M+100.3% | $50.0M+82.3% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $3.5M0.0% | $3.5M0.0% | $3.5M0.0% | $3.5M0.0% | $3.5M0.0% | $3.5M0.0% | $3.5M0.0% | $3.5M0.0% |
| Total Liabilities | $294.0M+113.8% | $276.0M+72.4% | $274.9M+100.4% | $146.9M+5.2% | $137.5M-13.4% | $160.1M-14.9% | $137.2M-30.4% | $139.7M-28.0% |
| Current Liabilities | $95.3M+68.7% | $75.8M+1.1% | $73.5M+37.5% | $69.5M+25.2% | $56.5M+25.8% | $74.9M+69.6% | $53.5M+0.8% | $55.5M+11.5% |
| Non-Current Liabilities | $198.7M+145.3% | $200.2M+135.3% | $201.3M+140.7% | $77.4M-8.0% | $81.0M-28.8% | $85.1M-40.9% | $83.7M-41.9% | $84.1M-41.7% |
| Long-Term Debt | $191.6M+173.4% | $192.8M | $193.6M | $69.3M-4.2% | $70.1M | N/A | N/A | $72.3M |
| Total Equity | $438.5M+1.7% | $408.2M+2.5% | $390.3M+4.5% | $477.3M+36.8% | $431.2M+85.9% | $398.3M+111.6% | $373.4M+142.9% | $349.0M+158.1% |
| Retained Earnings | -$28.6Mn/m | -$78.5Mn/m | -$116.3Mn/m | -$161.7Mn/m | -$211.0Mn/m | -$247.5Mn/m | -$281.7Mn/m | -$308.6Mn/m |
ADMA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $17.4M+30.7% | $29.5M+39.7% | $58.2Mn/m | $35.6M-29.0% | $13.3M-46.9% | $21.1M-53.7% | -$19.7Mn/m | $50.2M+185.4% |
| Depreciation & Amortization | $1.7M-15.0% | $1.7M-15.0% | $1.8M-5.3% | $2.0M0.0% | $2.0M+5.3% | $2.0M+5.3% | $1.9M0.0% | $2.0M+5.3% |
| Stock-Based Compensation | $6.2M+22.9% | $6.1M+23.6% | $6.3M+36.9% | N/A | $5.0M+58.8% | $5.0M+73.3% | $4.6M+116.0% | N/A |
| Capital Expenditures | $2.0M-86.1% | $2.3M-6.9% | $2.5M-45.9% | $1.1M-60.7% | $14.4M+1260.6% | $2.4M+17.2% | $4.7M+100.3% | $2.8M+130.3% |
| Free Cash Flow | $15.4Mn/m | $27.3M+45.8% | $55.7Mn/m | $34.6M-27.2% | -$1.1M-104.5% | $18.7M-57.1% | -$24.4Mn/m | $47.5M+189.4% |
| Investing Cash Flow | -$2.1Mn/m | -$2.3Mn/m | $2.4Mn/m | -$276Kn/m | -$14.4Mn/m | -$2.5Mn/m | -$4.7Mn/m | -$2.8Mn/m |
| Financing Cash Flow | -$26.8Mn/m | -$29.4M-61383.3% | -$10.1Mn/m | -$9.1Mn/m | -$27.8Mn/m | $48Kn/m | -$7.1Mn/m | -$31.0Mn/m |
| Share Buybacks | $25.1M+8.8% | $25.1Mn/m | $130.2Mn/m | $8.9Mn/m | $23.0M | $0 | $0 | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
ADMA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 70.8%+14.5pp | 69.4%+14.2pp | 70.5%+17.3pp | 63.8%+9.9pp | 56.3%+6.6pp | 55.1%+1.5pp | 53.2%+5.4pp | 53.9%+11.8pp |
| Operating Margin | 48.0%+10.0pp | 42.2%+7.1pp | 50.9%+20.5pp | 45.1%+12.5pp | 38.0%+4.9pp | 35.1%-1.5pp | 30.4%+3.7pp | 32.6%+13.3pp |
| Net Margin | 35.4%+8.2pp | 30.4%+2.3pp | 39.6%+16.1pp | 35.5%-59.7pp | 27.1%-2.8pp | 28.1%-1.9pp | 23.4%+1.7pp | 95.2%+119.1pp |
| Return on Equity | 11.4%+2.9pp | 9.3%+0.7pp | 11.6%+4.4pp | 10.3%-21.7pp | 8.5%-7.0pp | 8.6%-8.4pp | 7.2%-4.4pp | 32.1%+45.1pp |
| Return on Assets | 6.8%+0.4pp | 5.5%-0.6pp | 6.8%+1.5pp | 7.9%-15.0pp | 6.4%-2.8pp | 6.1%-2.4pp | 5.3%+0.2pp | 22.9%+28.3pp |
| Current Ratio | 6.04-1.1x | 6.97+1.6x | 6.95+0.4x | 6.71+0.7x | 7.130.0x | 5.33-1.5x | 6.58+1.4x | 5.97+0.8x |
| Debt-to-Equity | 0.44+0.3x | 0.47 | 0.50 | 0.15-0.1x | 0.16 | N/A | N/A | 0.21 |
| Liabilities-to-Equity | 0.67+0.4x | 0.68+0.3x | 0.70+0.3x | 0.31-0.1x | 0.32-0.4x | 0.40-0.6x | 0.37-0.9x | 0.40-1.0x |
| Asset Turnover | 0.190.0x | 0.180.0x | 0.17-0.1x | 0.220.0x | 0.24-0.1x | 0.22-0.1x | 0.220.0x | 0.240.0x |
| FCF Margin | 10.9%+11.7pp | 21.9%+6.6pp | 48.6%+69.9pp | 24.8%-15.5pp | -0.8%-20.8pp | 15.3%-25.3pp | -21.2%-15.6pp | 40.4%+18.2pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| ADMA Biologics, Inc. ADMA | FY2025 | $510.2M | $146.9M | 28.8% | $3.0B | 78/100 |
| Vericel Corporation VCEL | FY2025 | $276.3M | $16.5M | 6.0% | $3.0B | 57/100 |
| Acadia Pharmaceuticals Inc. ACAD | FY2025 | $1.1B | $391.0M | 36.5% | $3.1B | 68/100 |
| Telix Pharmaceuticals Limited TLX | FY2025 | $803.8M | -$7.1M | -0.9% | $3.0B | 44/100 |
| Zai Lab Limited ZLAB | FY2025 | $460.2M | -$175.5M | -38.1% | $2.8B | 67/100 |
| Legend Biotech Corporation LEGN | FY2025 | $1.0B | -$296.8M | -28.8% | $3.2B | 50/100 |
Where ADMA Biologics, Inc. Ranks
Frequently Asked Questions
ADMA Biologics, Inc. (ADMA) reported $510.2M in total revenue for fiscal year 2025. This represents a 19.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
ADMA Biologics, Inc. (ADMA) revenue grew by 19.6% year-over-year, from $426.5M to $510.2M in fiscal year 2025.
Yes, ADMA Biologics, Inc. (ADMA) reported a net income of $182.4M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $146.9M, with a net profit margin of 28.8%.
ADMA Biologics, Inc. (ADMA) had EBITDA of $199.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, ADMA Biologics, Inc. (ADMA) had $87.6M in cash and equivalents against $69.3M in long-term debt.
ADMA Biologics, Inc. (ADMA) had a gross margin of 57.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
ADMA Biologics, Inc. (ADMA) had an operating margin of 37.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
ADMA Biologics, Inc. (ADMA) had a net profit margin of 28.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
ADMA Biologics, Inc. (ADMA) has a return on equity of 30.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
ADMA Biologics, Inc. (ADMA) generated $27.8M in free cash flow during fiscal year 2025. This represents a -74.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
ADMA Biologics, Inc. (ADMA) generated $50.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
ADMA Biologics, Inc. (ADMA) had $624.2M in total assets as of fiscal year 2025, including both current and long-term assets.
ADMA Biologics, Inc. (ADMA) invested $22.6M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
ADMA Biologics, Inc. (ADMA) invested $4.8M in research and development during fiscal year 2025.
ADMA Biologics, Inc. (ADMA) had a current ratio of 6.71 as of fiscal year 2025, which is generally considered healthy.
ADMA Biologics, Inc. (ADMA) had a debt-to-equity ratio of 0.15 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
ADMA Biologics, Inc. (ADMA) had a liabilities-to-equity ratio of 0.31 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
ADMA Biologics, Inc. (ADMA) had a return on assets of 23.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
ADMA Biologics, Inc. (ADMA) trades at 16.5x earnings, its market capitalization divided by $182.4M net income, trailing 12 months to September 30, 2026. The market capitalization is $3.0B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
ADMA Biologics, Inc. (ADMA) trades at 5.8x sales, its market capitalization divided by $519.2M revenue, trailing 12 months to September 30, 2026. The market capitalization is $3.0B as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
ADMA Biologics, Inc. (ADMA) has an Altman Z-Score of 14.52, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
ADMA Biologics, Inc. (ADMA) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
ADMA Biologics, Inc. (ADMA) has an earnings quality ratio of 0.34x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
ADMA Biologics, Inc. (ADMA) has an interest coverage ratio of 26.93x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
ADMA Biologics, Inc. (ADMA) scores 78 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.